Tratamiento de la leishmaniasis visceral con miltefosina: Tres casos con infección VIH

• Autores: Juan Carlos López Corbalán, José Miguel Seguí Ripoll, José María Cuadrado Pastor
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 13, Nº. 5, 2011, págs. 306-308
• Idioma: español
• Títulos paralelos:
  • Treatment of visceral leishmaniasis with miltefosine in three cases with HIV infection
• Texto completo no disponible (Saber más ...)
• Resumen

  • We described 6 patients diagnosed with visceral leishmaniasis by the Infectious Diseases Unit from San Juan Hospital in Alicante, and reviewed anti-leishmanicidal treatments. We highlighted miltefosine as a powerful drug that produces a greater therapeutic adherence by being orally administered at a dose of 2.5 mg/kg of the patient's weight. It also shows a better tolerance versus the most toxic pentavalent antimonials, of required parenteral use, or versus Amphotericin B, both in the usual and liposomal fashion, which is more expensive, requires a hospital admission and is nephrotoxic